The company recorded an impairment loss of 8,095 million yen on affiliate shares of an overseas consolidated subsidiary whose fair value has significantly declined. This impairment charge is recorded as an extraordinary loss in the company's individual financial statements for Q3 FY2026, though it will be eliminated in consolidated financial statements.
¥8.1bn
›
Summary
The company recorded an impairment loss of 8,095 million yen on affiliate shares of an overseas consolidated subsidiary whose fair value has significantly declined. This impairment charge is recorded as an extraordinary loss in the company's individual financial statements for Q3 FY2026, though it will be eliminated in consolidated financial statements.
The company recorded a goodwill impairment loss of 4,862 million yen for TOMY International, Inc., its consolidated subsidiary in the United States, during the third quarter of fiscal year ending March 2026. The impairment was triggered by a review of business plans based on current business performance trends.
¥4.9bn
›
Summary
The company recorded a goodwill impairment loss of 4,862 million yen for TOMY International, Inc., its consolidated subsidiary in the United States, during the third quarter of fiscal year ending March 2026. The impairment was triggered by a review of business plans based on current business performance trends.